NCT04755075已完成1 期
A Phase 1 Study To Assess The Effect Of Hepatic Impairment On The Pharmacokinetics Of Surufatinib
Hutchison Medipharma Limited2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2021年2月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- AUC0-t
研究概览
简要总结
An open-label, multicenter, single-dose, single-period, sequential study to determine the effect of hepatic impairment on the PK of surufatinib.
详细描述
This is a phase 1, open-label, multicenter, single-dose, single-period, sequential study with the primary objective of determining the effect of moderate and mild hepatic impairment on the PK of surufatinib. The secondary objective is to evaluate the safety in subjects with moderate and mild (if enrolled) hepatic impairment and subjects with normal hepatic function.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •All Subjects
- •Male or female between 18 and 75 (inclusive)
- •Subject has BMI >18 and ≤40 kg/m^2 and body weight not ≤50 kg at screening.
- •The subject is a non-smoker or light smoker who smokes no more than 10 cigarettes, 2 cigars, 2 pipes, or other nicotine equivalents (eg, vape, snuff, gum) of tobacco per day; willing to limit smoking during the treatment period to 4 cigarettes or 1 cigar per day.
- •Females of non-childbearing potential or surgically sterile
- •Males who have not had a successful vasectomy and are partners of women of childbearing potential must use, or their partners must use, a medically acceptable method of contraception starting for at least 1 menstrual cycle prior to and throughout the entire study period, and for 2 weeks after the last dose of study drug. Those with partners using hormonal contraceptives must also use an additional approved method of contraception such as a condom with spermicide. Males who have had a successful vasectomy (confirmed azoospermia, documentation needed) require no additional contraception. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation.
- •Subjects with Hepatic Impairment
- •For moderate hepatic impairment, the subject must have a Child-Pugh score of 7 to
- •For mild hepatic impairment, the subject must have a Child-Pugh score of 5 to
- •The subject must have no clinically significant change in disease status within the last 30 days before screening.
- •If diabetic, the subject must have the disease controlled
- •Subjects with ascites must not have a paracentesis within 3 months of screening.
- •The subject must have blood pressure between 90 and 160 mm Hg systolic, inclusive, and not higher than 100 mm Hg diastolic.
- •Subjects with Normal Hepatic Function
- •The subject must be without hepatic disease and have normal hepatic function
- •The subject must be in good health
- •The subject must have blood pressure between 95 and 150 mm Hg systolic, inclusive, and no higher than 90 mm Hg diastolic
排除标准
- •All Subjects
- •The subject has evidence of clinically significant cardiovascular, GI, renal, respiratory, endocrine, hematological, neurological, or psychiatric disease or abnormalities.
- •The subject has a known history of any GI surgery or any condition possibly affecting drug absorption.
- •The subject has a clinically significant illness within 8 weeks or a clinically significant infection within 4 weeks prior to the first dose.
- •The subject has a clinically significant ECG abnormality
- •The subject has been diagnosed with acquired immune deficiency syndrome (AIDS), or tests positive for human immunodeficiency virus (HIV).
- •The subject has participated in a clinical study of another drug before dosing, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks before Day 1, whichever is longer, or is currently enrolled in another clinical study.
- •The subject has consumed grapefruit, starfruit, Seville oranges, or their products within 7 days prior to the first dose.
- •The subject has consumed herbal preparations/medications, including, but not limited to, kava, ephedra (ma huang), Ginkgo biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng, within 7 days prior to the first dose.
- •The subject has received blood or blood products within 8 weeks, or donated blood or blood products within 8 weeks prior to the first dose, or donated double red cells within 16 weeks prior to the first dose.
- •The subject has used any drug that is a strong inhibitor or inducer (including St. John's wort) of CYP3A or P-gp within 2 weeks prior to first dose or will require use during study treatment period.
- •The subject is allergic to the study drug or to any of its excipients.
- •Female subjects who are pregnant or planning to become pregnant, lactating, or breastfeeding.
- •The subject has used a proton pump inhibitor (PPI) within 4 days prior to the first dose or a histamine 2 (H2) receptor antagonist (H2 blocker) within 2 days prior to the first dose.
- •Subjects with Hepatic Impairment
- •The subject has clinically significant vital sign abnormalities at screening or baseline.
- •The subject has used acetaminophen at doses >1 g/day within 2 weeks prior to study drug administration.
- •The subject has a history or current diagnosis of uncontrolled or significant cardiac disease indicating significant risk of safety for participation in the study
- •The subject has Gilbert's syndrome, liver transplant, Wilson's disease, autoimmune liver disease
- •The subject has previously been diagnosed with hepatocellular carcinoma.
- •The subject has acute or exacerbating hepatitis, fluctuating or rapidly deteriorating hepatic function
- •The subject has a history of drug misuse within 6 months prior to screening or a positive drug test at screening or on Day -
- •The subject has evidence of current or recent abuse of alcohol
- •The subject has received therapy known to exacerbate hepatic impairment within 4 weeks of study drug administration.
- •The subject is taking antiviral therapy for treatment of active hepatitis infection at the time of screening.
- •Subjects with Normal Hepatic Function
- •The subject has evidence of clinically significant hepatic illness or abnormalities.
- •The subject has evidence of a clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations at screening or baseline.
- •The subject tests positive for Hepatitis B virus (HBV), HBsAg, Hepatitis C virus (HCV), or Hepatitis C antibody
- •The subject has used any prescription or nonprescription drugs, including over-the-counter (OTC) medications or vitamins, within 2 weeks prior to the first dose, unless otherwise specified.
- •The subject has a history of drug or alcohol misuse within 6 months prior to screening or a positive drug test at screening or on Day -1.
研究组 & 干预措施
Cohort 1
Experimental
Subjects with Normal Hepatic Function: All patients to receive study drug (Surufatinib 250mg) on Day 1
干预措施: Surufatinib (Drug)
Cohort 2
Experimental
Subjects with Moderate Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
干预措施: Surufatinib (Drug)
Cohort 3 (if enrolled)
Experimental
Subjects with Mild Hepatic Impairment: All patients to receive study drug (Surufatnib 250mg) on Day 1
干预措施: Surufatinib (Drug)
结局指标
主要结局
AUC0-t
时间窗: From Day 1 to Day 7
Area under the plasma concentration-time curve from time 0 to time of the last measurable concentration
AUC0-inf
时间窗: From Day 1 to Day 7
Area under the plasma concentration-time curve from time 0 to infinity (if data permit)
Cmax
时间窗: From Day 1 to Day 7
Maximum observed plasma concentration
次要结局
- Number of participants with treatment emergent adverse events as assessed by NCI CTCAE v5.0(From Day 1 to Day 7)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic FunctionHepatic ImpairmentNCT05674474Institut de Recherches Internationales Servier16
已完成
1 期
Pharmacokinetics of Imeglimin in Hepatic Impaired SubjectsHepatic ImpairmentNCT03802786Poxel SA14
已完成
1 期
Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy ParticipantsHepatic ImpairmentNCT05026996Novartis Pharmaceuticals17
已完成
1 期
A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)Hepatic Function AbnormalHealthy VolunteersNCT06444204Principia Biopharma, a Sanofi Company29
已完成
1 期
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855Symptomatic Neurogenic Orthostatic HypertensionnOHNCT04200573Theravance Biopharma31